endo international plc is a global specialty pharmaceutical company focused on improving the lives of patients while creating value. endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through our operating companies – endo pharmaceuticals, par pharmaceutical, paladin labs, somar and litha. endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from the dupont merck pharmaceutical company. since that time, the company has expanded to include the following business segments: u.s. branded pharmaceuticals, u.s. generic pharmaceuticals and international pharmaceuticals. endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. additionally, we are leveraging
Company profile
Ticker
ENDPQ, ENDPQ
Exchange
Website
CEO
Blaise Coleman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Endo International Ltd
SEC CIK
Corporate docs
Subsidiaries
70 Maple Avenue, LLC • Actient Pharmaceuticals LLC • Actient Therapeutics, LLC • Anchen Incorporated • Anchen Pharmaceuticals, Inc. • Astora Women's Health Bermuda ULC • Astora Women's Health Ireland Limited • Astora Women's Health, LLC • Auxilium International Holdings, LLC • Auxilium Pharmaceuticals, LLC ...
ENDPQ stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
18 Apr 24
8-K
Bankruptcy or Receivership
25 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Endo Reports Fourth-quarter 2023 Financial Results
6 Mar 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
8-K
Other Events
29 Dec 23
8-K
Endo Files Plan of Reorganization to Implement Previously Announced Sale Transaction
26 Dec 23
8-K
Other Events
30 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Endo Reports Third-quarter 2023 Financial Results
6 Nov 23
Transcripts
ENDPQ
Earnings call transcript
2022 Q1
6 May 22
ENDPQ
Earnings call transcript
2022 Q1
6 May 22
ENDPQ
Earnings call transcript
2021 Q4
1 Mar 22
ENDPQ
Earnings call transcript
2021 Q4
1 Mar 22
ENDPQ
Earnings call transcript
2021 Q3
5 Nov 21
ENDPQ
Earnings call transcript
2021 Q3
5 Nov 21
ENDPQ
Earnings call transcript
2021 Q2
7 Aug 21
ENDPQ
Earnings call transcript
2021 Q2
6 Aug 21
ENDPQ
Earnings call transcript
2021 Q1
7 May 21
ENDPQ
Earnings call transcript
2021 Q1
7 May 21
Latest ownership filings
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 23
SC 13G
BlackRock Inc.
8 Sep 22
SC 13G
MILLENNIUM MANAGEMENT LLC
29 Aug 22
4
James Patrick Tursi
17 Aug 22
SC 13G
BlackRock Inc.
8 Jul 22
SC 13G
MILLENNIUM MANAGEMENT LLC
27 Jun 22
4
Patrick A Barry
31 Mar 22
4
Frank B. Raciti
31 Mar 22
4
Matthew Joseph Maletta
31 Mar 22
4
Mark T. Bradley
31 Mar 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.08 bn | 1.08 bn | 1.08 bn | 1.08 bn | 1.08 bn | 1.08 bn |
Cash burn (monthly) | 11.46 mm | 17.34 mm | 5.63 mm | 18.28 mm | (no burn) | (no burn) |
Cash used (since last report) | 79.16 mm | 119.80 mm | 38.90 mm | 126.24 mm | n/a | n/a |
Cash remaining | 997.09 mm | 956.45 mm | 1.04 bn | 950.01 mm | n/a | n/a |
Runway (months of cash) | 87.0 | 55.1 | 184.2 | 52.0 | n/a | n/a |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Press releases
Paladin Labs Announces Approval of WAKIX® (pitolisant hydrochloride tablets) For Use in Pediatric Patients in Canada
28 Mar 24
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
26 Mar 24
Endo Announces Confirmation of Plan of Reorganization
19 Mar 24
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
12 Mar 24
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS
6 Mar 24